The Coronavirus disease 2019 (COVID-19) pandemic is a major public health issue. Right now, there is no vaccine to keep people from getting sick. There is also no treatment for people who do get sick. Researchers want to collect plasma from people who have recovered from COVID-19. The plasma will have antibodies against the virus that causes COVID-19.
If a vaccine is made, people who develop immunity from the vaccine can also donate plasma.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
To collect plasma from people who have recovered from COVID-19 or have been vaccinated against the coronavirus that causes COVID-19, so that the plasma can be used to treat people with the disease.
Study type: Observational
Estimated Enrollment: 1500 participants
Actual Study Start Date: April 8, 2020
Estimated Study Completion Date: April 20, 2042
All patients seen the in emergency room, admitted patients, or seen in outpatient clinics that are:
- Tested Positive for COVID-19 and recovered
- Suspected to have COVID 19 and validated with serological testing
- Suspected to have COVID 19 by symptoms, clinical course, and laboratory testing ruling out other respiratory viral disease
People volunteering to share their information to become part of this research pool of COVID-19 recovered individuals will complete an online survey.
Thank you for your interest in advancing COVID-19 treatments.
Please fill out this contact form to be connected to a member of the study team. The following information that you enter will only be authorized to be shared with the research team conducting this specific study.
If you have any difficulties or questions, please contact our support specialists at [email protected]
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you’ll be connected to the study team.